Affiliation:
1. Henry R. Bourne is professor emeritus in the Department of Cellular and Molecular Pharmacology at the University of California at San Francisco.
2. Mark O. Lively is a professor in the Department of Biochemistry at the Wake Forest School of Medicine, Winston-Salem, NC.
Abstract
A century ago, the unsinkable
Titanic
charged into a moonless night, full steam ahead. Today, unless it changes course to escape its own icebergs, the U.S. biomedical research enterprise hurtles toward a similar doom. The fiscal year 2012 budget of the U.S. National Institutes of Health (NIH) buys 18% less research than in 2004. On 2 January 2013, budget sequestration mandated by the Budget Control Act of 2011 could reduce NIH extramural funds still further, producing a staggering cumulative 41% decline in a single decade (in constant dollars, from 2004 to 2014), down to the level that NIH invested in 1997. In contrast, China's governmental support for biomedical research may double that of the United States, or even, in proportion to gross domestic product (GDP), quadruple it by 2017.
*
Publisher
American Association for the Advancement of Science (AAAS)
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献